These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37141836)

  • 21. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
    Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
    Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
    Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
    Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
    J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
    Dalal MR; Kazemi M; Ye F; Xie L
    Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia.
    Reviriego J; Gomis R; Marañés JP; Ricart W; Hudson P; Sacristán JA
    Int J Clin Pract; 2008 Jul; 62(7):1026-32. PubMed ID: 18489577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
    Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
    Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
    Krzymień J; Kobli T; Nazar M
    Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is hypoglycemia expensive in China?
    Lan K; Wang J; Nicholas S; Tang Q; Chang A; Xu J
    Medicine (Baltimore); 2021 Feb; 100(5):e24067. PubMed ID: 33592860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.
    Kern W; Holstein A; Moenninghoff C; Kienhöfer J; Riedl M; Kulzer B
    Exp Clin Endocrinol Diabetes; 2017 Oct; 125(9):592-597. PubMed ID: 28750429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
    Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
    Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ever-Increasing Insulin-Requiring Patients Globally.
    Garg SK; Rewers AH; Akturk HK
    Diabetes Technol Ther; 2018 Jun; 20(S2):S21-S24. PubMed ID: 29873518
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden.
    Jönsson L; Bolinder B; Lundkvist J
    Value Health; 2006; 9(3):193-8. PubMed ID: 16689714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Characteristics Associated With Severe Hypoglycemia in a Type 2 Diabetes Cohort in a Large, Integrated Health Care System From 2006 to 2015.
    Misra-Hebert AD; Pantalone KM; Ji X; Milinovich A; Dey T; Chagin KM; Bauman JM; Kattan MW; Zimmerman RS
    Diabetes Care; 2018 Jun; 41(6):1164-1171. PubMed ID: 29549082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The burden of severe hypoglycemia in type 2 diabetes.
    Liu J; Wang R; Ganz ML; Paprocki Y; Schneider D; Weatherall J
    Curr Med Res Opin; 2018 Jan; 34(1):179-186. PubMed ID: 29017368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the severity of hypoglycemia on health - Related quality of life, productivity, resource use, and costs among US patients with type 2 diabetes.
    Pawaskar M; Iglay K; Witt EA; Engel SS; Rajpathak S
    J Diabetes Complications; 2018 May; 32(5):451-457. PubMed ID: 29496365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budget impact of treating commercially insured type 1 and type 2 diabetes patients in the United States with insulin degludec compared to insulin glargine.
    Weatherall J; Bloudek L; Buchs S
    Curr Med Res Opin; 2017 Feb; 33(2):231-238. PubMed ID: 27764979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in rates of hypoglycemia and health care costs in patients treated with insulin aspart in pens versus vials.
    Asche CV; Luo W; Aagren M
    Curr Med Res Opin; 2013 Oct; 29(10):1287-96. PubMed ID: 23865725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.